MAPPING GENETIC HEART DISEASES

PLN. Our heart muscle disease belongs to the group of rare heart diseases that can have serious consequences for over thousands of gene carriers in the Netherlands and abroad. As a patient, you are looking for the best possible care, an accurate diagnosis and the proper (more…)
More

HELP SCIENTISTS TO UNDERSTAND

The PHOspholamban RElated CArdiomyopathy STudy (PHORECAST) aims to investigate several aspects of the PLN p.Arg14del mutation and the carriers of this gene mutation. Some of these research projects include PLN p.Arg14del mutation carriers and (more…)
More

PLN RESEARCH PROJECT 2017-2022

The transatlantic project The PLN disease is a currently uncurable heart muscle disease caused by a genetic mutation in the DNA. Carriers of this mutation are exposed to a major health risk which may express itself in moderate to very serious heart failure, arrhythmias and sudden premature death. (more…)
More

ENTRESTO: NEW DRUG FOR HEART FAILURE

A recent large study has shown that the new drug Entresto has a very positive effect on patients with heart failure: patients are able to live longer and are less often hospitalized due to heart failure. This is probably a medical progression in the treatment of chronic heart failure. (more…)
More

CARDIAC GENE THERAPY IN DEVELOPMENT

Gene therapy for the treatment of chronic heart failure ** A promising gene therapy will soon be tested in trials in the United States on persons. NanoCor Therapeutics has developed an experimental treatment called “Carfostin”: it has recently been accepted as experimental drug. (more…)
More